The guiding principle behind the formulation design was to use only serum components at serum levels.
AQIX® RS-I, ( 'I' standing for Inotropic) the company’s lead product, is a patented, universal volume replacement for human serum and interstitial fluid.
The guiding principle behind the formulation design was to use only serum components at serum levels. A direct comparison of the patented formulation of AQIX® RS-I to that of serum and interstitial fluid is shown below.
Human Serum mmol/L
|Organic acid||5 (BES)||6.4 (Imidazole)||7.0|
|Aspartate||20 µmols/L||1-11 µmols/L||cf. serum|
|Carnitine||50 µmols/L||35-85 µmols/L||cf. serum|
|Choline||10 µmols/L||18-70 µmols/L||cf. serum|
|Thiamine Pyrophosphate||40 nmols/L||6-135 nmols/L||cf. serum|
|Human insulin||28 mIU/L||6-35 mIU/L||24 mIU/L|
|pH @ 37°C||7.30-7.46||7.32-7.45||7.35-7.38|
The Benefits of AQIX® RS-I
- Human and animal cells, tissues and organs can be kept viable both hypothermically and normothermically for significantly longer periods than previously achieved with conventional media.
- Cell membrane receptors of all cell types are held in an optimal, sensitized state and react as they would in-vivo.
- AQIX® RS-I can improve the predictability of preclinical potency and safety assays.
If you would like to trial a sample of AQIX® RS-I for research applications or require further information, please contact us using the contact section of the web site.